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study question: What medical and psychological variables predict why men with banked sperm do not return for semen analysis
after their cancer treatment has ended?
summary answer: Men who decline the offer of semen analysis are less likely to have reported adverse side effects during cancer
treatment, and have a more negative experience of banking sperm and a more negative attitude towards disposal of their stored semen than
those who attend.
what is known already?: Previous authors have noted that male cancer survivors seem reluctant to have their fertility tested
after their treatment has ended. Moreover, the utilization rates of banked sperm are very low (,10%) and the majority of samples are kept
for many years without being used.
study design, size and duration: A cross-sectional study of 499 cancer survivors who were sent a questionnaire about their
views on sperm banking, fertility and post-treatment semen analysis between April 2008 and December 2010.
participants and setting: Men (aged 18–55 years) who had banked sperm in Shefﬁeld and Nottingham (UK) prior to gona-
dotoxic treatment for cancer more than 5 years previously.
main results and the role of chance: Completed questionnaires were received from 193 men (38.7% response rate)
whose samples had been banked for 9.18+3.70 years (range ¼ 4.94–26.21) and whose current age was 35.08+ 7.08 years (range ¼
21.58–54.34; mean+ SD). One-third (35.8%) had never attended for semen analysis. In multivariate analysis, the odds of not attending
for semen analysis were signiﬁcantly greater among men who did not experience adverse treatment side effects [odds ratio (OR) ¼ 5.72,
95% conﬁdence interval (CI) ¼ 2.10–15.56], who reported a more negative experience of banking sperm (OR ¼ 1.82, 95% CI ¼ 1.17–
2.82) and a more negative attitude to disposal of their stored semen (OR ¼ 1.56, 95% CI ¼ 1.01–2.42).
limitations and reasons for caution: Only 38.7% of those eligible agreed to take part. We do not know the character-
istics of men who declined to take part, if they agreed to attend semen analysis without completing the questionnaire or whether they had
chosen to have semen analysis performed elsewhere (e.g. private sector). Some of the measures used (e.g. experience of banking sperm)
relied on men’s recall of events many years previously.
wider implications of the findings: New strategies are required to encourage these men to engage with fertility monitor-
ing programmes if sperm banks are to be used cost-effectively and men are to be given appropriate fertility advice.
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Introduction
Sperm banking is now a routine procedure recommended for all post-
pubertal males where there is a risk of long-term infertility following
cancer treatment (European Society forHumanReproductionandEmbry-
ology, 2004; National Collaborating Centre for Women’s and Children’s
Health, 2004; Lee et al.,2006;RoyalCollegeofPhysicians, 2007).Although
many thousands of men each year decide to bank sperm following a diag-
nosis of cancer, most of our knowledge is limited to technical descriptions
of how sperm are frozen (Tomlinson and Pacey, 2003), semen quality at
the timeof banking (e.g. Bahaduret al., 2005), case histories of pregnancies
following the use of thawed sperm many years later (Horne et al., 2004;
Feldschuh et al., 2005) and reports on the rate of utilization of banked
samples (reviewed in Pacey and Eiser, 2011).
In a recent review, Pacey and Eiser (2011) concluded that little is
known about the decisions men make concerning their banked sperm,
apart fromwhether or not to bank sperm at the time of cancer diagnosis.
In subsequent years, men must also decide whether or not to monitor
fertility through regular semen analysis. Critically, for many cancer survi-
vors, the timescale for making these decisions can extend substantially
beyond discharge from cancer care. These survivors may not have
access to oncologists or reproductive medicine specialists but have to
rely on their own recall of information about fertility given at banking
and the more general knowledge of primary care doctors.
The monitoring of fertility by men with banked sperm is of interest
because spermatogenesis may recommence in a substantial number of
patients following completion of cancer treatment (Tomlinson and
Pacey, 2003; Bahadur et al., 2005; Pacey, 2007). However, interviews
with 19menwhohad banked spermat least 5 years previously suggested
that they were often unaware that their fertility could recover (Eiser
et al., 2011), and that they saw no point in attending for semen analysis
simply to be told that their semen quality remained poor. This may con-
tribute to observations by healthcare professionals (Wasserman et al.,
1987; Tomlinson and Pacey, 2003; Van Casteren et al., 2008) that
men with banked sperm seem reluctant to attend for semen analysis.
Suggesting men have regular semen analysis following the end of
cancer treatment would seem to be good advice, since the information
can facilitate their decisions about appropriate use of contraception, or
where necessary referral for Assisted Conception. In addition, in coun-
tries such as the UK, fertility monitoring through semen analysis serves
an important regulatory function, as men can now only keep banked
samples in the longer term if ‘signiﬁcant or premature infertility’ is
demonstrated (Human Fertilisation and Embryology Authority, 2009).
The implications are that if UKmen decline to attend for semen analysis,
then there is a genuine risk that their samples may be removed from
storage and destroyed, even if they remain subfertile.
Given the need to better understand the decisions men make about
monitoring their fertility after cancer treatment has ended, we con-
ducted a cross-sectional study to quantify the percentage of men
who did not accept invitations for semen analysis and to identify
medical and psychological variables contributing to their decision.
Materials and Methods
Patients
Between April 2008 and December 2010 we contacted a cohort of 499
men who had banked sperm more than 5 years previously prior to
gonadotoxic treatment for cancer. Eligibility criteria included age (18–55
years), no known mental health problems, and sufﬁcient English language
ability to provide written informed consent and complete questionnaires.
Setting
Men were recruited from sperm banks located in Shefﬁeld Teaching Hos-
pitals NHS Foundation Trust (Jessop Wing, Tree Root Walk, Shefﬁeld,
UK) and Nottingham University Hospitals NHS Trust (Queen’s Medical
Centre, Derby Road, Nottingham, UK).
Recruitment procedures
In both facilities, men with banked sperm are written to regularly to invite
them to attend for semen analysis, conﬁrm or renew their consent for
storage or give permission for disposal of banked samples. We included
with this standard letter an information sheet and consent form, an
11-page questionnaire (see below) and a prepaid return envelope. Men
were asked to return the questionnaire, regardless of whether or not
they decided to attend semen analysis. The Trent Research Ethics Com-
mittee approved these procedures prior to the start of the study (Ref:
07/H0405/61).
Information from medical and sperm bank
records
Information on diagnosis, treatment regimen, attendance at oncology
follow-up appointments and late effects was obtained from medical
records held in oncology. Information about banked sperm (number of
samples stored and their quality) was obtained from separate notes held
at each sperm bank. We also collected information about the number
of prior letters/appointments sent to the patient inviting him for semen
analysis and the number of times he attended. Where men had attended
for semen analysis details of the results were also recorded. Only limited
medical data could be collected for 26 patients (one patient’s notes had
been destroyed and notes were unavailable for 25 patients), but data
from sperm bank records were obtained for all patients.
Questionnaire
The questionnaire included the following nine sections Q1. Multiple choice
responses and ﬁve-point Likert rating scales with appropriate endpoints
were used.
(i) Health and well-being (Ware et al., 1995). The SF-12v2 is a widely
used and validated 12-item measure generating two summary scores:
physical component summary (PCS) and mental component summary
(MCS). Higher scores indicate better quality of life.
(ii) Current late effects and perceived vulnerability (Absolom et al.,
2006). This includes 17 cancer-related health problems, or ‘late effects’,
known to occur after cancer treatment (e.g. infertility, fatigue and depres-
sion) to assess men’s views about their ‘vulnerability’ to late effects (range
¼ 1–5) with higher scores indicating greater perceived vulnerability, and
total ‘number of late effects’ currently experienced (0–17).
(iii) Experience of banking sperm. This scale was developed speciﬁcally for
this study and includes 11 items about men’s experience of banking sperm
(e.g. ‘I had the right amount of support from others in making this choice’
and ‘I am pleased I decided to bank’). Higher scores indicated a more
negative experience of banking sperm.
(iv) Information about fertility. We assessed four separate aspects of
men’s information about their fertility. These included how many
samples they recalled banking, the quality of their banked samples (‘did
not have any sperm to bank’, ‘good enough for fertility treatment’ or
‘don’t know’), how useful it was to know the quality of banked sperm
(ﬁve-point scale from ‘deﬁnitely very useful’ to ‘deﬁnitely not very
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useful’), and current use of contraception, and if not why (rely on partner,
trying for a child, not in a relationship, fertility too low).
(v) Views about follow-up. This specially developed scale included seven
questions regarding men’s attitude to returning for semen analysis (e.g.
‘I don’t want to know if my fertility has recovered or not’, ‘I am certain
my fertility has already or will recover’ and ‘I don’t think it’s worth
taking time off work for this’). Higher scores indicated a more positive at-
titude to returning for semen analysis.
(vi) Attitude to disposal. Eight questions were used to assess men’s atti-
tudes to disposal (e.g. ‘If tests showed my fertility was recovered, I would
agree to disposal’, ‘Knowing I still had sperm banked would make me feel
more conﬁdent’). Higher scores indicate a more negative attitude to
disposal.
(vii) Children and parenting. Five items were used to assess men’s attitude
to having children in future (‘How much has your experience of cancer
affected your wish to have children in future’, ‘How much do you want
to have a child in future’, ‘I worry that children born from banked
sperm will have health problems’, ‘I worry that my cancer treatment
could cause health problems for any child born afterwards’ and ‘Before
your cancer diagnosis, were you ever worried that you had fertility pro-
blems’). Men were also asked about the number of biological children con-
ceived with their own sperm or with banked sperm in assisted conception,
the number of adopted children or step-children they see regularly and the
number of children conceived using donor sperm.
(viii) Demographic information. Information was collected about current
age, relationship status (single/separated or partnered), age left full time
education (under 18 or over 18 years of age), current employment
(working or not working), ethic group (white or other) and who they
live with (partner or other). This section also recorded the ﬁrst four
digits of the UK postcode of their primary residence in order to calculate
distance from the sperm bank.
Analysis
All data were double entered into SPSS version 16 and checked for accur-
acy. Nineteen cases had some missing data on continuous questionnaire
variables. Little’s Missing Completely At Random (MCAR) test (Little,
1988) showed the pattern of missing data were not signiﬁcantly related
to other predictor variables (P ¼ 0.48). These missing values were
replaced through imputation using the expectation maximization (EM) al-
gorithm in SPSS missing value analysis (Tabachnick and Fidell, 2007). All
continuous variables were standardized prior to analysis.
Independent samples t-tests and x2 analyses were used to examine any
differences between the two recruitment sites. The relationship between
non-attendance for semen analysis and demographic, medical/laboratory
and psychological variables was examined using univariate logistic regres-
sions. The extent to which these simple relationships were independent
of each other in predicting non-attendance was determined by multivari-
able hierarchical logistic regression analysis.
All naturally continuous variables were entered as predictors in logistic
regression models. Following Hosmer and Lemeshow (2000), we tested
for signiﬁcant non-linearity in the relationship of the continuous predictors
with the logit of the dependent variable. We found no evidence this as-
sumption was violated in any analysis and there was no evidence the mul-
tiple predictor models suffered from multicollinearity.
Treatment of scales
Reliability analyses were conducted for all scales and were good for health
and well-being (Ware et al., 1995: the Cronbach alpha for PCS and MCS
was 0.83 and 0.85, respectively); current late effects and perceived vulner-
ability (Absolom et al., 2006: alpha ¼ 0.92 and for the scales experience of
banking sperm (alpha ¼ 0.64) and attitudes to disposal (alpha ¼ 0.84).
However, initial reliability for the other scales fell below that considered
acceptable and further analyses were conducted.
A principal component exploratory factor analysis with varimax rotation
on the items in ‘Views about follow-up’ resulted in a two-factor solution
explaining 56.8% of the variance. We identiﬁed a scale to measure ‘Im-
portance of fertility monitoring’ that included three items; ‘I don’t want
to know if my fertility has recovered or not’, ‘Information about the
quality of my sperm will make no difference to my behaviour’ and ‘I
don’t think it’s worth taking time off work to ﬁnd out about my fertility’
(Cronbach’s alpha ¼ 0.73). A second factor reﬂected ‘Conﬁdence in fer-
tility recovery’: ‘I am certain my fertility has already or will recover’ and
‘I am conﬁdent my fertility is normal/as good as any other man of my
age’ (Cronbach’s alpha ¼ 0.93).
The same procedure was conducted for the scale children and parenting
(alpha ¼ 0.41) but no simple factor structure was identiﬁed. All ﬁve items
of the ‘children and parenting’ scale were subsequently analysed
separately.
Differences between sperm banks
Both of the sperm banks in Shefﬁeld and Nottingham were established in
the mid-1980s and are similar in size and organization. Each is licensed by
the Human Fertilisation and Embryology Authority and during the study
was managed alongside specialist Andrology Laboratories that undertook
diagnostic procedures according to World Health Organisation (1999)
methods for local General Practitioners, Gynaecologists and Urologists
as well as men who had banked sperm there. Both were members of
the UK National External Quality Assurance Schemes in Andrology.
While some laboratory methods (e.g. the technique used to measure
semen volume) and aspects of sperm bank administration (e.g. the style
and content of previous letters to patients) were different between the
sperm banks, they were not considered to be relevant to the study and
data from both sited were combined.
Results
Of the 499 men eligible to participate in the study, 193 (Shefﬁeld ¼
114; Nottingham ¼ 79: response rate of 38.7%) consented and
returned completed questionnaires (Fig. 1). The mean age+ standard
deviation was 35.05+7.08 years (range ¼ 21.58–54.34) and their
samples had been banked for 9.18+3.70 years (range ¼ 4.94–
26.21). Men were on average 26.00+6.45 years old (range ¼
14.18–42.46) at the time their samples were banked.
The most common diagnosis was Testicular cancer (n ¼ 85: 44.0%),
followed by Lymphoma (n ¼ 46: 23.8%), Leukaemia (n ¼ 28: 14.6%)
and other cancers (n ¼ 17: 8.8%). No diagnosis information was avail-
able for 17 men (8.8%). Thirty-seven (19.2%) experienced a relapse
subsequent to the original diagnosis and underwent further cycles of
treatment [time between initial treatment and treatment for relapse
was 2.15 years+2.08 (range ¼ 0.22–9.01 years)].
Treatment information was available for 159 men, of whom 54.7%
(n ¼ 87) had received chemotherapy, 15.7% (n ¼ 25) radiotherapy
and 22.6% (n ¼ 36) a combination of both. No treatment had been
given to the remaining 6.9% (n ¼ 11) who were maintained on a sur-
veillance protocol: of these 10 had been diagnosed with testicular
cancer and one was recorded as ‘other’.
Overall, 35.8% [95% conﬁdence interval (CI) ¼ 28.9–42.7, n ¼ 69]
had never attended semen analysis, 32.6% (95% CI ¼ 25.9–39.3, n ¼
63) had attended only once and 31.6% (95% CI ¼ 24.7–38.5, n ¼ 61)
had attended twice or more. Attenders had returned between one
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and six times (mean ¼ 1.83+1.15). Preliminary analysis revealed few
differences between men who had attended once and those who had
attended twice or more so these groups were combined (Fig. 1). Sub-
sequent comparisons were made between ‘non-attenders’ (n ¼ 69)
and ‘attenders’ (n ¼ 124). There was no signiﬁcant association
between non-attendance for semen analysis and oncology follow-up
post-treatment (x2(1) ¼ 2.65; P ¼ 0.104).
Non-attenders were signiﬁcantly more likely to report being un-
employed (29 versus 16.4%, respectively) and single (30.4 versus
13.0%, respectively) compared with attenders (Table I). Non-
attenders were less likely to have adverse treatment side effects
recorded in their oncology notes (11.9 versus 37.6%) and had been
sent signiﬁcantly fewer letters of invitation to attend for semen analysis
(3.67+1.74 versus 4.31+2.06; Table II).
Non-attenders were signiﬁcantly more likely to report a negative
experience of sperm banking (1.94+0.47 versus 1.80+ 0.39) or
knowing the quality of their banked sperm was less useful (1.84+
0.86 versus 1.56+0.74) and a more negative attitude to disposal of
their stored semen (3.56+0.75 versus 3.27+ 0.83) than men who
had attended (Table III).
In a subsequent multivariate hierarchical logistic regression, the
demographic, medical and psychological variables identiﬁed above
were entered in three steps (Table IV). Only three of these variables
contributed uniquely to ‘non-attendance’. The odds of being a non-
attender were signiﬁcantly greater for men who did not experienced
adverse treatment side effects [odds ratio (OR) ¼ 5.72, 95% CI ¼
2.10–15.56], for men who reported a more negative experience of
banking sperm (OR ¼ 1.82, 95% CI ¼ 1.17–2.82) and men with a
more negative attitude to disposal (OR ¼ 1.56, 95% CI ¼ 1.01–2.42).
Discussion
The ﬁrst aim of this study was to determine the proportion of men
who did not return for semen analysis after banking sperm following
cancer treatment. Approximately one-third (35.8%) of men in our
sample had declined all invitations to attend for semen analysis over
the 5–26-year period that their sperm had been banked. Previous
authors (e.g. Wasserman et al., 1987; Tomlinson and Pacey, 2003)
have commented that cancer survivors seem reluctant to attend for
semen analysis, but this has not been examined systematically. Van
Casteren et al. (2008) noted that 61% of 557 men had not returned
for semen analysis over an average follow-up period of 7 years
(range ¼ 2–23), considerably higher than in our study population.
Second, we sought to identify signiﬁcant predictors of non-
attendance. These included being single and unemployed (Table I),
but neither of these demographic variables remained signiﬁcant
when taking into account medical and psychological variables. This
was also true of the number of times men had been sent reminder
letters to attend (Table II). How useful men considered it to know
the quality of banked sperm also contributed to predicting non-
attendance but again not when taking into account other variables
that were measured (Table III). There was no difference between
attenders and non-attenders in diagnosis or the type of treatment
given.
Our multivariate analysis identiﬁed three variables that contributed
uniquely to the decision men made to decline the offer of attending for
semen analysis. A substantial effect was seen in relation to the pres-
ence or absence of treatment side effects recorded in the oncology
records. The odds of non-attending were 5.72 times greater for
men who did not experience side effects compared with men who
experienced them (Table IV). It is possible that men not experiencing
these symptoms may have felt their cancer treatment was less
........................................................................................
Table I Univariate logistic regressions of demographic
variables to identify predictors of non-attendance for
semen analysis.
Variable n (%) OR
(95% CI)
Signiﬁcance
Age (years) 1.16
(0.87–1.57)
0.315
Relationship
status
Single 155 (80.7%) 2.90
(1.39–6.04)
0.005
Partner (Ref) 37 (19.3%)
Age left full time
education
Under 18 year 108 (56.2%) 0.81
(0.45–1.47)
0.484
Over 18 years
(Ref)
84 (43.8%)
Employment
Not working 40 (20.8%) 2.08
(1.03–4.22)
0.042
Working (Ref) 152 (79.2%)
Ethnic group
White 184 (95.8%) 0.55
(0.13–2.26)
0.403
Other (Ref) 8 (4.2%)
Living status
Other 61 (31.8%) 0.74
(0.39–1.38)
0.339
Partner (Ref) 131 (67.9%)
Number of
children
1.06
(0.79–1.42)
0.711
Current distance
from sperm bank
1.29
(0.96–1.75)
0.095
On continuous variables ORs are for a one standard deviation increase.
aDemographics missing for one patient Q5.
Signiﬁcance level P, 0.05 (in bold).
Figure 1 Summary of recruitment to the study and attendance for
semen analysis by participants.Q4
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‘damaging’ and therefore assumed their fertility was less likely to be
affected. However, there was no difference between attenders and
non-attenders in terms of any late effects men reported either now
or in terms of their perception of their future vulnerability (Table II).
In addition to treatment-related side effects, men’s initial ‘experi-
ence of banking sperm’ was also associated with attendance, with
those reporting a more negative experience more likely to be subse-
quent non-attenders. This measure included 11 items to assess experi-
ence, but it was not possible with the current data to identify exactly
which aspects of the process coloured attendance. However, data
from an interview study (Eiser et al., 2011) suggest that men view
sperm banking as just part of their oncology journey, accepting the
oncologist’s advice and keeping appointments at the sperm bank in
the same way that they keep appointments for other aspects of
their treatment care plan, such as blood tests and scans. A negative
experience recorded in this scale may therefore reﬂect more than
what happened within the conﬁnes of the Sperm Bank, but include
other aspects of how the process was managed within the oncology
team. Crawshaw et al. (2008) highlighted some of the other difﬁculties
young men can experience, including practical difﬁculties to do with
transport, or pressures from family members. If these ﬁndings are
replicated, the implications are that initial negative experience of
banking sperm or general oncological care may jeopardize the prob-
ability of a patient returning for semen analysis in the future.
Finally, men with more negative attitudes to disposal were less likely
to attend for semen analysis. This may suggest that men are aware that
one of the purposes of semen analysis is to consider the options
regarding disposal. In previous work, we have found that men are
often reluctant to agree to disposal even when they have no wish
for children, in part because they see stored semen as a protection
against future disease recurrence (Eiser et al., 2011). We suggest
that men’s reluctance to attend is a strategy they adopt to ensure
they are put under no pressure to dispose. In fact, given the current
requirements of the Human Fertilisation and Embryology Authority
.............................................................................................................................................................................................
Table II Univariate logistic regressions of (a) oncology and (b) andrology variables to identify predictors of
non-attendance for semen analysis.
Variable n (%) OR (95% CI) Signiﬁcance
(a) Oncology variables
Diagnosis
Testicular 85 (48.3%) 1.15 (0.62–2.12) 0.665
Other (Ref) 91 (51.7%)
Treatment
Chemotherapy 87 (54.7%) 0.57 (0.16–2.03) 0.385
Radiotherapy 25 (15.7%) 0.94 (0.23–3.92) 0.936
Combined 36 (22.6%) 0.53 (0.13–2.10) 0.365
No treatment (Ref) 11 (16.9%)
Treatment side effects
Yes 54 (32.1%) 5.63 (2.35–3.45) <0.001
No (Ref) 114 (67.9%)
Other medical conditions
Yes 32 (19.0%) 1.57 (0.72–3.45) 0.258
No (Ref) 136 (81.0%)
Participation in clinical trial
Yes 43 (74.4%) 0.64 (0.30–1.37) 0.253
No (Ref) 125 (25.6%)
Not attendance at oncology follow-up
Yes 39 (27.3%) 1.91 (0.89–4.08) 0.097
No (Ref) 104 (72.7%)
Late effects recorded
Yes 64 (37.9%) 0.61 (0.31–1.20) 0.150
No (Ref) 105 (62.1%)
(b) Andrology variables
Number of samples banked – 1.30 (0.95–1.77) 0.104
Time banked (years) – 1.06 (0.98–1.15) 0.157
Prebanking semen quality (motile concentration) – 1.00 (0.99–1.01) 0.997
Number of invitations for semen analysis – 0.84 (0.71–0.99) 0.033
(Ref), reference category. Signiﬁcance level P, 0.05 (in bold).
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(2009), it is now more likely that those who do not attend, and there-
fore cannot demonstrate on-going infertility, may ﬁnd their samples
have been disposed after the initial 10 year consent period has
elapsed.
It is interesting to consider those variables that were unrelated to
whether or not men return for semen analysis. These include demo-
graphic variables such as age, number of biological children and level of
education as well as oncology variables such as diagnosis, treatment
and attendance at oncology follow-up. The fact that there was no re-
lationship between non-attendance for semen analysis and oncology
follow-up post-treatment suggests that our results do not simply
reﬂect a general reluctance in these men to attend medical
appointments.
There are considerable challenges in work of this kind, not least the
difﬁculty of engaging men in the research process. Only 38.7% of those
eligible agreed to take part. Similar reluctance of men to take part in
studies concerned with fertility (Stewart et al., 2009) or post-
vasectomy testing schedules (Chawla et al., 2004) has been described.
This may be related to the general stereotype that men seem reluctant
to be involved in health care decisions (Kraemer, 2000). We do not
know the characteristics of men who declined to take part and
whether or not they agreed to attend semen analysis without com-
pleting the questionnaire, nor do we know if any of them chose to
have semen analysis performed elsewhere (e.g. private sector). This
has implications beyond the interpretation of our study, since health-
care policy and advice given to patients about the prospect of recover-
ing spermatogenesis is informed from audits which do not take into
account the fact that not all men with banked sperm may have been
tested (cf. Bahadur et al., 2005). We cannot conclude that men did
not attend for semen analysis because they had fathered more chil-
dren (and therefore knew they were fertile) because there was no dif-
ference in family size between attenders and non-attenders (Table I).
Second, some of the measures used in this study (e.g. experience of
banking sperm) relied on men’s recall of events many years previously.
We know that cancer patients typically have a great deal of informa-
tion to remember, much of which (40–80%) is forgotten immediately
.............................................................................................................................................................................................
Table III Univariate logistic regressions to identify psychological predictors of non-attendance for semen analysis.
Variable OR (95% CI) Signiﬁcance
Health and well-being
PCS 1.00 (0.96–1.03) 0.857
MCS 1.01 (0.98–1.04) 0.569
Current late effects and perceived vulnerability
Perceived vulnerability 1.05 (0.78–1.42) 0.733
Total cancer problems 0.77 (0.55–1.08) 0.131
Experience of banking sperm 1.39 (1.03–1.88) 0.032
Information about fertility
Quality of banked sperma
Good enough for fertility treatment 0.65 (0.34–1.22) 0.179
Do not know (Ref)
Usefulness of knowing quality of banked sperm 1.41 (1.04–1.90) 0.025
Use of contraceptiona
Never 0.65 (0.31–1.37) 0.254
Sometimes 0.61 (0.25–1.49) 0.280
All the time (Ref)
Views to follow-up
Conﬁdence in fertility recovery 0.89 (0.67–1.20) 0.456
Importance of fertility monitoring 0.99 (0.74–1.34) 0.994
Attitude to disposal 1.47 (1.06–2.03) 0.020
Children and parenting
Inﬂuence of cancer on wish for children in the future 1.06 (0.78–1.42) 0.726
Want for children in the future 0.91 (0.68–1.21) 0.506
Worry of health problems for future children using banked sperm 1.11 (0.82–1.49) 0.508
Worry of health problems for future children from cancer 1.10 (0.82–1.48) 0.525
Concerns about fertility before cancer 1.11 (0.83–1.48) 0.488
Predictors are standardized continuous scales unless otherwise indicated.
aCategorical predictor variables.
Signiﬁcance level P, 0.05 (in bold).
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and half recalled incorrectly (Kessels, 2003). If the same is true of
men’s recall of events that took place at the time of sperm banking,
then we need to interpret these results with caution.
Although our ﬁndings suggest attendance for semen analysis was
better than found in some earlier work (e.g. Van Casteren et al.,
2008) attendance is still considerably below optimal. Our distinction
between attenders and non-attenders was based on attendance at
least once, but as all those involved in this study were relatively long-
term survivors it means the majority had missed some appointments.
The challenge of encouraging attendance is considerable in that after a
decade many men have been discharged from oncology follow-up and
may recall little of the information given to them when they ﬁrst
banked sperm (Eiser et al., 2011). In these circumstances, it is interest-
ing to consider what men themselves gain from undergoing semen
analysis.
We suggest that men may perceive there are few tangible beneﬁts
in attending for semen analysis. Attendance can bring to mind previous
negative experiences around time of diagnosis, and raise questions
about ongoing infertility that challenge self-esteem (Eiser et al.,
2011) and precipitate discussion about unwanted disposal. It is also
easy to identify barriers to attendance including the need to ask for
time off work.
Timely letters from the sperm bank may encourage attendance, but
it is important to include clear information about possible beneﬁts (e.g.
access to assisted conception or information about changes to fertil-
ity). Framing information in terms of these beneﬁts rather than focus-
ing on disposal may contribute to improved attendance. Given the
current UK Legislation that banked sperm can only be stored
beyond 10 years if there is evidence of ‘signiﬁcant or premature infer-
tility’ (Human Fertilisation and Embryology Authority, 2009), it is
essential that men become better informed about the rationale under-
lying semen analysis. Our study suggests that this may involve correct-
ing assumptions about the possible recovery of fertility after cancer
treatment, and emphasizing the unlikely relationship between cancer
treatment side effects and subsequent infertility.
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Table IV Multivariate hierarchical logistic regression of demographic, medical and psychological variables predicting
non-attendance for semen analysis (OR and 95% CIs are shown).
Variable Demographic
(R2 5 0.06 (Nagelkerke))
Demographic1medical
(R25 0.21 (Nagelkerke))
Demographic1
medical1 psychological
(R25 0.30 (Nagelkerke))
OR (95% CI) Signiﬁcance OR (95%CI) Signiﬁcance OR (95% CI) Signiﬁcance
Relationship
status (single)a
2.27 (0.97–5.34) 0.060 1.86 (0.75–4.62) 0.181 1.77 (0.68–4.59) 0.240
Employment Status
(not working)a
1.73 (0.77–3.92) 0.186 1.74 (0.73–4.14) 0.209 1.25 (0.49–3.18) 0.641
No treatment side
effectsa
5.83 (2.27–14.96) <0.001 5.72 (2.10–15.56) 0.001
Number of contacts
(laboratory to patient)
0.81 (0.56–1.16) 0.251 0.70 (0.47–1.05) 0.083
Experience of banking
sperm
1.82 (1.17–2.82) 0.007
Attitudes to disposal 1.56 (1.01–2.42) 0.048
Usefulness of knowing
quality of banked sperm
1.21 (0.79–1.86) 0.373
Predictors are standardized continuous scales unless otherwise indicated.
aCategorical predictor variables (for reference groups, see Tables I and III).
Signiﬁcance level P, 0.05 (in bold).
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